This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• Needham analyst Ami Fadia downgraded Centessa Pharmaceuticals plc (NASDAQ:CNTA) from Buy to Hold. Centessa Pharmaceuticals shares closed at $27.58 on Monday. See how other analysts view this stock.
• Baird analyst Joseph Vruwink downgraded Phreesia, Inc. (NYSE:PHR) from Outperform to Neutral and lowered the price target from $25 to $10. Phreesia shares closed at $11.41 on Monday. See how other analysts view this stock.
• D. Boral Capital analyst Jason Kolbert downgraded Plus Therapeutics, Inc. (NASDAQ:PSTV) from Buy to Hold. Plus Therapeutics shares closed at $0.2146 on Monday. See how other analysts view this stock.
• Jefferies analyst Stephen Volkmann downgraded Rockwell Automation, Inc. (NYSE:ROK) from Buy to Hold and cut the price target from $490 to $380. Rockwell Automation shares closed at $348.51 on Monday. See how other analysts view this stock.
• Benchmark analyst Bruce D. Jackson downgraded Humacyte, Inc. (NASDAQ:HUMA) from Buy to Speculative Buy and slashed the price target from $10 to $1. Humacyte shares closed at $0.5745 on Monday. See how other analysts view this stock.

Considering buying CNTA stock? Here’s what analysts think:

Photo via Shutterstock